Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis
- 28 August 2019
- journal article
- research article
- Published by Springer Nature in Pediatric Drugs
- Vol. 21 (5) , 389-395
Abstract
Introduction Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by interleukin (IL)-1 overproduction. Colchicine is the mainstay drug in the treatment of FMF; however, a minority of patients do not respond despite the highest tolerated doses. We aimed to share our experience with canakinumab, a human monoclonal antibody against IL-1β, in pediatric FMF patients. Methods This historical, single-cohort study retrospectively evaluated the disease characteristics, indications, and treatment responses of 14 pediatric FMF patients treated with canakinumab in our pediatric rheumatology department. Results The median age at onset and diagnosis of 14 FMF patients (9 females, 5 males), were 3.5 (range 0.5–10) years and 6 (range 3–16) years, respectively. Indications for canakinumab treatment were renal amyloidosis (n = 1), colchicine resistance (n = 11), and persistent arthritis (n = 2). Only two (14.3%) patients had colchicine intolerance. Complete response was obtained in 10/14 (71.5%) among all patients and 10/12 (86%) in patients with typical phenotype. The patient with chronic oligoarthritis had a complete response, whereas the patient with rheumatoid factor (RF)-positive polyarthritis demonstrated an initial partial response to canakinumab treatment. We found that attack frequency, proteinuria, and acute phase reactants, including erythrocyte sedimentation rate and C-reactive protein, were significantly decreased after canakinumab treatment in children with FMF. Conclusion Canakinumab may be an effective treatment option for pediatric FMF patients with colchicine resistance, renal amyloidosis, and chronic oligoarthritis. Further studies are needed to clarify the efficacy of canakinumab in patients with a second disease, RF-positive polyarticular juvenile idiopathic arthritis.Keywords
This publication has 28 references indexed in Scilit:
- Long-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patientsModern Rheumatology, 2019
- Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysisSao Paulo Medical Journal, 2019
- Canakinumab for the Treatment of Autoinflammatory Recurrent Fever SyndromesNew England Journal of Medicine, 2018
- Canakinumab treatment in children with familial Mediterranean fever: report from a single centerRheumatology International, 2018
- Familial Mediterranean fever in childhood: a single-center experienceRheumatology International, 2017
- The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean feverMolecular and Cellular Pediatrics, 2016
- Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean feverArthritis Research & Therapy, 2015
- Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patientsModern Rheumatology, 2014
- Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the LiteratureSeminars in Arthritis and Rheumatism, 2011
- Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding studyBMC Musculoskeletal Disorders, 2011